Last reviewed · How we verify
NGX-4010
NGX-4010 is a topical capsaicin patch that desensitizes nociceptors (pain-sensing nerve fibers) by depleting substance P, reducing localized pain transmission.
NGX-4010 is a topical capsaicin patch that desensitizes nociceptors (pain-sensing nerve fibers) by depleting substance P, reducing localized pain transmission. Used for Postherpetic neuralgia (PHN), Peripheral neuropathic pain.
At a glance
| Generic name | NGX-4010 |
|---|---|
| Sponsor | NeurogesX |
| Drug class | Topical analgesic; TRPV1 agonist |
| Target | TRPV1 (transient receptor potential vanilloid 1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Neurology |
| Phase | Phase 3 |
Mechanism of action
The patch delivers high-concentration capsaicin (8%) directly to affected skin, causing initial activation followed by prolonged desensitization of TRPV1-expressing C-fibers. This leads to depletion of the neuropeptide substance P, which is critical for pain signal transmission, resulting in sustained analgesia in the treated area. The mechanism is particularly effective for neuropathic pain conditions where localized nerve damage causes chronic pain.
Approved indications
- Postherpetic neuralgia (PHN)
- Peripheral neuropathic pain
Common side effects
- Application site erythema
- Application site pain/burning
- Application site pruritus
- Transient increase in local pain
Key clinical trials
- A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment (PHASE4)
- A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain
- Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (PHASE3)
- Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN) (PHASE2)
- Effect of NGX-4010 on ENFD and Sensory Function (PHASE1)
- Study of NGX-4010 for the Treatment of Postherpetic Neuralgia (PHASE3)
- Study of NGX-4010 for the Treatment of Postherpetic Neuralgia (PHASE3)
- Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NGX-4010 CI brief — competitive landscape report
- NGX-4010 updates RSS · CI watch RSS
- NeurogesX portfolio CI